RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial

Enisamium is an orally available therapeutic that inhibits influenza A virus and SARS-CoV-2 replication. We evaluated the clinical efficacy of enisamium treatment combined with standard care in adult, hospitalized patients with moderate COVID-19 requiring external oxygen. Hospitalized patients with...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Olga Holubovska, Pavlo Babich, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Lutz Mueller, Aartjan J. W. te Velthuis, Victor Margitich, Andrew Goy
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-05-01
coleção:	Advances in Respiratory Medicine
Assuntos:	COVID-19 SARS-CoV-2 clinical trial RNA polymerase antiviral FAV00A
Acesso em linha:	https://www.mdpi.com/2543-6031/92/3/21
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!